NICE approves vedolizumab for Crohn's disease

The integrin inhibitor vedolizumab (Entyvio) has been approved by NICE for use in moderately to severely active Crohn's disease after prior therapy.

Vedolizumab targets α4β7 integrin, which is responsible for the recruitment of white blood cells to inflamed bowel tissue. | SCIENCE PHOTO LIBRARY
Vedolizumab targets α4β7 integrin, which is responsible for the recruitment of white blood cells to inflamed bowel tissue. | SCIENCE PHOTO LIBRARY

NICE has deemed that patients eligible for NHS treatment with vedolizumab are those with moderate to severe disease who have failed treatment with a tumour necrosis factor (TNF) inhibitor, or for whom such treatment is unsuitable.

Further information
NICE technology appraisal TA352
Patients should continue treatment with vedolizumab until the drug stops working or surgery is needed, or for 12 months, whichever is shorter. Patients should be reassessed at 12 months and treatment continued only if there is clear evidence of clinical benefit.

For patients who achieve complete remission by 12 months consideration should be given to stopping treatment, with the option to resume if a relapse occurs. Patients continuing with treatment past the initial 12 months should be reassessed at least annually to determine whether continued treatment is justified.

NHS approval was granted on the basis that the drug is supplied by the manufacturer with the discount agreed in the patient access scheme.

NICE has also approved vedolizumab for use in moderately to severely active ulcerative colitis.


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.